NCT00946946 - Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

May 31, 2007

Study Completion Date

July 31, 2009

Conditions

Crohn's Disease

Interventions

DRUG

Azathioprine

2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets

DRUG

Mesalazine

4g Mesalazine tablets/day AND azathioprine placebo tablets

DRUG

Azathioprine placebo

4g Mesalazine tablets/day AND azathioprine placebo tablets

DRUG

Mesalazine placebo

2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets

Trial Locations (2)

Universitaetsklinik für Innere Medizin III, Abteilung Gastroenterologie and Hepatologie, Vienna

Robert-Bosch Krankenhaus, Innere Medizin I, Stuttgart